By contrast, elafin has been found to promote cell proliferation through its activation of the MAP kinase pathway, and it has been associated with chemoresistance via Bcl-Xl expression in high-grade serous ovarian cancers and basal-like breast tumors [25]. Here, BCL2L1 is linked to breast neoplasm.